This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Martin H. Schaffer, MD
Department of Psychiatry The University of Chicago Chicago, IL 60637

John M. Davis, MD
Illinois State Psychiatric Institute University of Illinois—Chicago Chicago, IL 60612

Carol A. Tamminga, MD
Maryland Psychiatric Research Center University of Maryland Baltimore, MD 21228

Arch Gen Psychiatry. 1985;42(9):927.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.—

Some controversy has developed recently over the antipsychotic efficacy of apomorphine in schizophrenic psychosis, including an article by Levy et al1 in the ARCHIVES.² It is our opinion that a definitive answer to this question requires a broader experimental approach than that attempted by the investigators in either of these groups. Previously, Corsini and co-workers^3,4 reported apomorphine's marked antipsychotic action when given in a dose of 1 mg subcutaneously to a group of unmedicated schizoaffective patients. Tamminga et al,⁵ in a double-blind placebocontrolled study, showed an equally dramatic effect of a 3-mg subcutaneous dose given to a group of chronic schizophrenic and schizoaffective subjects who were maintained on a neuroleptic regimen.⁵

Those drug trials reporting antipsychotic activity of apomorphine in a controlled design are characterized by at least two features. First, a range of apomorphine doses, including high levels, were used in the . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?